Peter T Scardino
Overview
Explore the profile of Peter T Scardino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
403
Citations
17431
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Touijer K, Vertosick E, Sjoberg D, Liso N, Nalavenkata S, Melao B, et al.
Eur Urol
. 2024 Oct;
87(2):253-260.
PMID: 39472200
Background And Objective: Lymph node dissection (LND) has been standard in cancer surgery for more than a century, yet evidence from randomized trials showing a benefit is scarce. We conducted...
2.
Perera M, Assel M, Nalavenkata S, Khaleel S, Benfante N, Carlsson S, et al.
Clin Genitourin Cancer
. 2024 Sep;
22(6):102204.
PMID: 39260095
Background: During active surveillance (AS) for Grade Group (GG) 2 prostate cancer, pathologic progression to GG3 on surveillance biopsy is a trigger for intervention. However, this ratio of GP3:GP4, may...
3.
Flores J, Vertosick E, Jenkins L, Cooper J, Benfante N, Sjoberg D, et al.
J Urol
. 2024 Jan;
211(3):400-406.
PMID: 38194487
Purpose: There have been conflicting studies on the association between phosphodiesterase type 5 inhibitor (PDE5i) use and biochemical recurrence (BCR) following radical prostatectomy (RP). Our aim was to determine whether...
4.
Musser J, Assel M, Meeks J, Sjoberg D, Vickers A, Coleman J, et al.
Urol Pract
. 2023 Aug;
2(3):121-125.
PMID: 37559295
Introduction: We evaluated the safety and efficacy of a clinical pathway designed and implemented to transition inpatient minimally invasive radical prostatectomy to a procedure with overnight observation. Methods: In April...
5.
Pellegrino F, Sjoberg D, Tin A, Benfante N, Briganti A, Montorsi F, et al.
World J Urol
. 2023 May;
41(6):1489-1495.
PMID: 37209144
Purpose: To determine whether β-microseminoprotein or any of the kallikrein forms in blood-free, total or intact PSA or total hK2-predict metastasis in patients with evidence of detectable levels of PSA...
6.
Fine S, Al-Ahmadie H, Vertosick E, Vickers A, Chen Y, Gopalan A, et al.
Urol Pract
. 2023 May;
9(5):459-465.
PMID: 37145713
Introduction: Our goal was to determine whether zonal origin of anterior dominant prostate cancers is associated with clinical outcome among patients treated with radical prostatectomy. Methods: We investigated the clinical...
7.
Ouyang X, Jessen W, Al-Ahmadie H, Serio A, Lin Y, Shih W, et al.
Cancer Res
. 2023 Apr;
83(7):1161.
PMID: 37014042
No abstract available.
8.
Perera M, Jibara G, Tin A, Haywood S, Sjoberg D, Benfante N, et al.
Eur Urol Focus
. 2022 Dec;
9(4):662-668.
PMID: 36566100
Background: Active surveillance (AS) is recommended as the preferred treatment for men with low-risk disease. In order to optimize risk stratification and exclude undiagnosed higher-grade disease, most AS protocols recommend...
9.
Perera M, Lebdai S, Tin A, Sjoberg D, Benfante N, Beech B, et al.
Urol Oncol
. 2022 Nov;
41(2):105.e19-105.e23.
PMID: 36435708
Background: Pathologic nodal invasion at prostatectomy is frequently associated with persistently elevated prostate-specific antigen (PSA) and with increased risk of disease recurrence. Management strategies for these patients are poorly defined....
10.
Clements M, Lin X, Gmelich C, Vertosick E, Vickers A, Manasia M, et al.
Urol Pract
. 2022 Oct;
8(5):535-540.
PMID: 36238352
Purpose: We implemented an advanced practice provider (APP)-led clinic to aid in managing the growing population of men on active surveillance (AS) for prostate cancer. Our objective was to evaluate...